|ALSO KNOWN AS||N-Phenylacetyl-L-prolylglycine ethyl ester, GVS-111|
|TYPE||Nootropic Agent, Central Stimulant, Anxiolytic Agent, Antidepressive Agents|
Memory, attention and other cognitive functions, and emotionally liable disorder, including those in advance aged patients with:
Noopept is a nootropic drug with nootropic and neuroprotective properties. Improves learning ability, memory, working on all phases of processing: the primary information processing, consolidation, retrieval. Prevents the development of amnesia caused by electroshock, a blockade of central cholinergic structures glutamatergic receptor systems ironic phase of sleep deprivation.
Neuroprotective effect Noopept appears to improve the stability of brain tissue to the damaging effects (trauma, hypoxia, electro, toxic) and alleviating the degree of damage to brain neurons. The drug reduces the amount of focus on thrombotic models of stroke and prevents the loss of neurons in tissue culture cortex and cerebellum, expose neurotoxic concentrations glutamate, free radical oxygen.
Noopept has antioxidant effects, antagonistic effects on the effects of excess calcium, improves the rheological properties of blood, with antiplatelet, fibrinolytic, anticoagulant properties.
Nootropic effect of the drug is associated with the formation of cycloprolylglycine, similar to the structure of an endogenous cyclic dipeptide having anti-amnesiatic activity, as well as to the availability choline's positive action.
Noopept increases the amplitude of the trans-callosal response, making associations between the cerebral hemispheres at the level of these cortical structures more possible.
Noopept helps to restore memory and other cognitive functions, disturbed by the damaging effects – brain injury, local and global ischemia, prenatal damage (alcohol, hypoxia).
Therapeutic effect of the drug in patients with organic disorders of central nervous system manifests itself, beginning with 5-7 days of treatment. Initially implemented in the spectrum of activity Noopept has anyxiolytic and easy stimulatory effects, manifested in the reduction or disappearance of anxiety, increased irritability, affective liability, sleep disturbance. After 14-20 days of treatment revealed the positive impact of the drug on cognitive function, the parameters of attention and memory.
Noopept has a vegetative normalizing effect which helps to reduce headaches, and orthostatic tachycardial episodes. Noopept is not cumulative in the body, does not cause drug dependence with the cessation of the drug .
Noopept does not cause injury to internal organs, does not lead to changes in haematological and biochemical parameters, has no immuno-toxic, teratogenic effects, and showed no mutagenic properties.
|DOSAGE||20 - 30 mg per day, split into 2 – 3 administrations of 10mg each|
|STACKED WITH||Piracetam, Pramiracetam, Oxiracetam, Phenylpiracetam, Noopept, Choline, Alpha GPC, Citicoline, Centrophenoxine, DMAE, Phosphatidylcholine, Adderall, Modafinil (Provigil), Phenibut|
|ATC CODE||Nootropic Tool N06BX|
|CAS REGISTRY NUMBER||157115-85-0|
|MOLECULAR WEIGHT||318.367 g/mol|
|ABSOPRTION||Noopept is absorbed into the gastrointestinal tract, and enters the bloodstream unaltered, it then crosses the blood-brain barrier and is found at higher concentrations within the brain.|
|BIOLOGICAL HALF-LIFE||0.38 hours|